Kush Parmar Sells 92,444 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Kush Parmar sold 92,444 shares of Entrada Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $7.00, for a total transaction of $647,108.00. Following the sale, the director directly owned 2,691,337 shares of the company’s stock, valued at $18,839,359. This represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kush Parmar also recently made the following trade(s):

• On Friday, August 7th, Kush Parmar sold 52,317 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $358,371.45.
• On Thursday, August 6th, Kush Parmar sold 10,494 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.00, for a total value of $73,458.00.
• On Friday, July 31st, Kush Parmar sold 1,718 shares of Entrada Therapeutics stock. The shares were sold at an average price of $6.85, for a total value of $11,768.30.
• On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.93, for a total value of $795,259.08.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $7.04 on Wednesday. Entrada Therapeutics, Inc. has a 1 year low of $5.02 and a 1 year high of $16.45. The stock has a 50 day simple moving average of $6.87 and a two-hundred day simple moving average of $9.65. The firm has a market cap of $274.14 million, a P/E ratio of -1.78 and a beta of -0.26.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $2.32 million. On average, equities analysts anticipate that Entrada Therapeutics, Inc. will post -4.07 earnings per share for the current year.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP increased its position in shares of Entrada Therapeutics by 4.3% in the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after acquiring an additional 206,911 shares during the period. BlackRock Inc. purchased a new stake in shares of Entrada Therapeutics during the second quarter worth about $19,013,000. Wellington Management Group LLP grew its stake in shares of Entrada Therapeutics by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the last quarter. Millennium Management LLC grew its stake in shares of Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after purchasing an additional 666,287 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Entrada Therapeutics by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after purchasing an additional 42,479 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. HC Wainwright cut Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Guggenheim lowered their target price on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, June 8th. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. Finally, Roth Capital set a $10.00 target price on Entrada Therapeutics in a report on Friday, May 8th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Entrada Therapeutics presently has an average rating of “Hold” and an average price target of $17.50.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Institutional ownership remains high at approximately 86.4%. BlackRock opened a position worth about $19.0 million, while Millennium Management, Citadel Advisors and Qube Research increased their holdings. These purchases may provide some underlying demand for TRDA shares.
• Positive Sentiment: Analyst coverage remains mixed but includes three Buy ratings. The average price target is reported at $17.50, well above recent trading levels, although HC Wainwright downgraded the stock to Neutral and Guggenheim lowered its target to $17.00. Entrada Therapeutics analyst and stock information
• Neutral Sentiment: Reported short interest was zero shares, with a zero-day days-to-cover ratio. Because the data also shows an “NaN” change from the prior period, it offers little reliable insight into current short-selling pressure.
• Negative Sentiment: Major shareholder Ventures V. L.P. 5Am sold a combined 62,811 shares on August 6 and 7 for approximately $431,829, reducing its position by about 2.2%. The shareholder still owns more than 2.7 million shares, so the sales represent a modest reduction rather than a full exit. SEC filing on Ventures V. L.P. 5Am share sales
• Negative Sentiment: Director Kush Parmar sold 155,255 shares across three transactions from August 6 through August 10 for roughly $1.08 million, cutting his holdings by approximately 5.5%. Repeated insider selling can weigh on sentiment, even though he continues to hold a substantial stake. SEC filing on Kush Parmar share sales
• Negative Sentiment: Entrada’s latest quarterly results missed expectations: adjusted loss per share was $1.01 versus an expected $0.97 loss, while revenue of $0.90 million fell short of the $2.32 million consensus. The clinical-stage biotechnology company is expected to remain unprofitable, with analysts forecasting a full-year loss of approximately $4.07 per share.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.